Division of Dermatology and Venereology, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Dermatology. 2012;225(4):326-32. doi: 10.1159/000345715. Epub 2013 Jan 16.
Although clinical studies have shown efficacy of biological agents in moderate to severe psoriasis, observational studies of real-world effectiveness are rare.
To analyse the psoriasis area and severity index (PASI) and quality of life by the EQ-5D questionnaire and dermatology quality of life index (DLQI) in psoriasis patients who switched from conventional systemic treatment to biological agents in clinical practice. Furthermore, to analyse patient groups with the highest benefit of biological agents.
Longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Psoriasis, PsoReg. Outcomes of biological-naïve patients who switched to a biological agent (n = 267) were analysed before switch and at the first follow-up.
Patients significantly improved in EQ-5D, DLQI and PASI (p < 0.001). Patients with DLQI ≥10 and/or PASI ≥10 had the greatest benefits from biological agents in terms of EQ-5D.
Patients with moderate to severe psoriasis benefit from biological agents in clinical practice; the patients with the highest benefits were those with high pretreatment PASI and DLQI scores.
尽管临床研究表明生物制剂在中重度银屑病中的疗效，但关于真实世界有效性的观察性研究却很少。
在临床实践中，分析从传统系统治疗转为生物制剂的银屑病患者的银屑病面积和严重程度指数（PASI）和生活质量（通过 EQ-5D 问卷和皮肤病生活质量指数（DLQI）），并分析生物制剂获益最高的患者群体。
这是一项基于瑞典国家系统治疗银屑病登记处（PsoReg）的纵向观察性研究。分析了 267 名首次转为生物制剂的生物制剂初治患者在转换前和首次随访时的结局。
患者在 EQ-5D、DLQI 和 PASI 方面均有显著改善（p<0.001）。DLQI≥10 和/或 PASI≥10 的患者从生物制剂中获益最大，表现在 EQ-5D 方面。
中重度银屑病患者从生物制剂治疗中获益，高预处理 PASI 和 DLQI 评分的患者获益最大。
